Dutch founder SDHB exon 3 deletion in patients with pheochromocytoma-paraganglioma in South Africa

Debra M. Gordon, Pablo Beckers, Emilie Castermans, Sebastian J.C.M.M. Neggers, Liliya Rostomyan, Vincent Bours, Patrick Petrossians, Vinciane Dideberg, Albert Beckers, Adrian F. Daly*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
24 Downloads (Pure)


Objective: Screening studies have established genetic risk profiles for diseases such as multiple endocrine neoplasia type 1 (MEN1) and pheochromocytoma–paraganglioma (PPGL). Founder effects play an important role in the regional/national epidemiology of endocrine cancers, particularly PPGL. Founder effects in the Netherlands have been described for various diseases, some of which established themselves in South Africa due to Dutch emigration. The role of Dutch founder effects in South Africa has not been explored in PPGL. Design: We performed a single-center study in South Africa of the germline genetic causes of isolated/syndromic neuroendocrine tumors. Methods: Next-generation panel, Sanger sequencing and multiplex ligand-dependent probe amplification for endocrine neoplasia risk genes. Results: From a group of 13 patients, we identified 6 with PPGL, 4 with sporadic or familial isolated pituitary adenomas, and 3 with clinical MEN1; genetic variants were identified in 9/13 cases. We identified the Dutch founder exon 3 deletion in SDHB in two apparently unrelated individuals with distinct ethnic backgrounds that had metastatic PPGL. Asymptomatic carriers with this Dutch founder SDHB exon 3 deletion were also identified. Other PPGL patients had variants in SDHB, and SDHD and three MEN1 variants were identified among MEN1 and young-onset pituitary adenoma patients. Conclusions: This is the first identification of a Dutch founder effect for PPGL in South Africa. Awareness of the presence of this exon 3 SDHB deletion could promote targeted screening at a local level. Insights into PPGL genetics in South Africa could be achieved by studying existing patient databases for Dutch founder mutations in SDHx genes.

Original languageEnglish
Article numbere210560
JournalEndocrine Connections
Issue number1
Publication statusPublished - 31 Jan 2022

Bibliographical note

Funding Information:
The study was supported in part by a grant from the Fonds pour la recherche scientifique (FIRS), CHU de Liege 2017?2020.

Publisher Copyright:
© 2022.


Dive into the research topics of 'Dutch founder SDHB exon 3 deletion in patients with pheochromocytoma-paraganglioma in South Africa'. Together they form a unique fingerprint.

Cite this